17/10/2017 ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING
(WorldNews Belgium)

ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING GHENT, Belgium, 17 October 2017 - Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need, announced today that it intends to offer and sell, subject to market and other conditions, approximately $175 million of its ordinary shares in a global offering, which is comprised of a public offering in the United States and Canada of ordinary shares in the form of American Depositary Shares ("ADS"), and an offer of ordinary shares in Europe and countries...